サンプル依頼リスト カート
  • English
デフォルト表紙
市場調査レポート
商品コード
1776217

経鼻ドラッグデリバリー：市場洞察・競合情勢・市場予測 (～2032年)

Intranasal Drug Delivery - Market Insights, Competitive Landscape, and Market Forecast - 2032

出版日
発行
DelveInsight
ページ情報
英文 150 Pages
納期
2～10営業日
カスタマイズ可能
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=150.39円
経鼻ドラッグデリバリー：市場洞察・競合情勢・市場予測 (～2032年)
出版日: 2025年07月01日
発行: DelveInsight
ページ情報: 英文 150 Pages
納期: 2～10営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 図表
  • 目次
概要

経鼻ドラッグデリバリーの市場規模は、2024年の644億5,120万米ドルから、予測期間中はCAGR 6.24％で推移し、2032年には1,042億4,863万米ドルに達すると予測されています。

この成長は主に、神経疾患、呼吸器疾患、重度のアレルギー疾患、眼科疾患などの慢性疾患の有病率の上昇によって推進されています。迅速な効果を持ち、非侵襲的である薬剤投与法への需要が高まっていることも市場拡大に寄与しており、特に経鼻投与は、吸収が早く使用が容易であるという利点から、患者の服薬遵守率および治療効果の向上に貢献しています。さらに、研究開発活動の活発化や主要企業による製品発売の増加も、この分野の技術革新を加速させています。これらの進展により、より効率的かつ標的を絞った経鼻治療の開発が促進され、市場は活性化し競争力を増しています。こうした一連の動向が、場の継続的成長にとって有利な環境を形成しており、2025年から2032年にかけて力強く安定した拡大が見込まれています。

経鼻ドラッグデリバリーの市場力学：

世界保健機関 (WHO) が2024年に発表したデータによれば、2023年にはてんかんの患者数が全世界で約5,000万人に達し、神経疾患の中でも最も一般的なものの一つとなっています。特に、約80％が低・中所得国に集中しており、これらの地域ではタイムリーな治療へのアクセスが依然として限られています。こうした環境では、医療従事者による監督なしでも使用できる実用的かつ即効性のある経鼻投与は、有効な代替手段となります。このようにてんかん症例の増加が市場の成長を後押ししており、経鼻薬は、てんかん患者における発作の急性期対応に用いられています。

同様に、うつ病も依然として世界的な健康問題です。WHOによると、2023年には世界で推定2億8,000万人がうつ病に罹患していました。経鼻治療は、治療抵抗性うつ病に対する効果的な治療法として台頭しており、迅速な症状緩和と簡便な投与法により、特に外来や救急の現場での需要を創出しています。これが、経鼻ドラッグデリバリーソリューションへの需要増加をもたらしています。

世界の糖尿病負担も急速に増加しています。国際糖尿病連合 (2023年) によると、2021年には糖尿病患者数は5億3,700万人で、2030年には6億4,300万人、2045年には7億8,300万人に増加すると予測されています。グルカゴンのようなホルモンの革新的な経鼻製剤は、注射療法に代わる非侵襲的で即効性のある代替療法を提供し、肝代謝をバイパスしながら糖尿病患者の急性低血糖を管理するのに役立ちます。したがって、糖尿病患者の増加が経鼻ドラッグデリバリー市場の成長を促進しています。

世界的に糖尿病の負担も急速に増加しています。国際糖尿病連盟 (IDF) の2023年のデータによれば、2021年には20～79歳の成人5億3,700万人が糖尿病を患っており、この数は2030年には6億4,300万人、2045年には7億8,300万人に増加すると予測されています。グルカゴンなどのホルモンを経鼻で投与する革新的な製剤は、非侵襲的かつ即効性のある注射代替手段を提供し、肝初回通過代謝を回避しながら低血糖の急性管理に貢献しています。このため、糖尿病の増加は市場成長をさらに後押ししています。

また、慢性疼痛や片頭痛も世界中で多くの人々に影響を与えています。欧州疼痛学会連合 (2023年) によると、2023年には約1億5,000万人の欧州人が慢性疼痛に悩まされており、WHOの推計では2021年に片頭痛およびその他の頭痛疾患が世界で約31億人に影響を与えたとされています。経鼻薬は、急性片頭痛発作の管理に用いられ、消化管を経由せずに迅速に効果を発揮することから、その需要が高まっています。

当レポートでは、世界の経鼻ドラッグデリバリーの市場を調査し、市場概要、市場影響因子および市場機会の分析、法規制環境、市場規模の推移・予測、各種区分・地域/主要国別の詳細分析、競合情勢、主要企業のプロファイルなどをまとめています。

目次

第1章 経鼻ドラッグデリバリー市場レポート：イントロダクション

第2章 経鼻ドラッグデリバリー市場のエグゼクティブサマリー

  • 市場概要

第3章 競合情勢

第4章 規制分析

  • 米国
  • 欧州
  • 日本
  • 中国

第5章 経鼻ドラッグデリバリー市場：主要要因分析

  • 市場促進要因
    • 慢性疾患の増加
    • 速効性と非侵襲性の薬剤投与に対する需要の高まり
    • 疾患の分野における主要企業による研究開発活動と製品発売の増加
  • 市場抑制要因と課題
    • 鼻腔内薬剤投与に伴う複雑さと限界
    • 製品承認のための厳格な規制要件
  • 市場の機会
    • ナノ製剤と個別化医療の進歩

第6章 経鼻ドラッグデリバリー市場：ポーターのファイブフォース分析

第7章 経鼻ドラッグデリバリー市場の評価

  • 剤形別
    • スプレー
    • 滴・液体
    • ゲル
    • 粉末
  • 容器別
    • 加圧
    • 非加圧
  • システム別
    • 単位用量システム
    • バイドーズシステム
    • マルチドーズシステム
  • 用途別
    • 呼吸器疾患
    • 神経疾患
    • 感染症
    • その他
  • 流通チャネル別
    • 病院薬局
    • オンライン薬局
  • 地域別
    • 北米
    • 欧州
    • アジア太平洋
    • その他の地域

第8章 経鼻ドラッグデリバリー市場：企業・製品プロファイル

  • Pfizer Inc.
  • Johnson & Johnson Services, Inc.
  • EMERGENT
  • UCB S.A.
  • GSK plc
  • Amphastar Pharmaceuticals, Inc.
  • Neurelis, Inc.
  • Hikma Pharmaceuticals PLC
  • Perrigo Company
  • ARS Pharmaceuticals Operations, Inc.
  • AstraZeneca
  • Therakind
  • AFT Pharmaceuticals
  • Teva Pharmaceutical Industries Ltd.
  • Currax Pharmaceuticals LLC
  • Impel Pharmaceuticals LLC
  • Endo, Inc.
  • Procter & Gamble
  • Teleflex Incorporated
  • Viatris Inc.
  • Amneal Pharmaceuticals LLC

第9章 KOLの見解

第10章 プロジェクトアプローチ

第11章 DelveInsightについて

第12章 免責事項・問い合わせ

図表

List of Tables

  • Table 1: Competitive Analysis
  • Table 2: Intranasal Drug Delivery Market in Global (2022-2032)
  • Table 3: Intranasal Drug Delivery Market in Global by Dosage Form (2022-2032)
  • Table 4: Intranasal Drug Delivery Market in Global by Container (2022-2032)
  • Table 5: Intranasal Drug Delivery Market in Global by System (2022-2032)
  • Table 6: Intranasal Drug Delivery Market in Global by Application (2022-2032)
  • Table 7: Intranasal Drug Delivery Market in Global by Distribution Channel (2022-2032)
  • Table 8: Intranasal Drug Delivery Market in Global by Geography (2022-2032)
  • Table 9: Intranasal Drug Delivery Market in North America (2022-2032)
  • Table 10: Intranasal Drug Delivery Market in the United States (2022-2032)
  • Table 11: Intranasal Drug Delivery Market in Canada (2022-2032)
  • Table 12: Intranasal Drug Delivery Market in Mexico (2022-2032)
  • Table 13: Intranasal Drug Delivery Market in Europe (2022-2032)
  • Table 14: Intranasal Drug Delivery Market in France (2022-2032)
  • Table 15: Intranasal Drug Delivery Market in Germany (2022-2032)
  • Table 16: Intranasal Drug Delivery Market in United Kingdom (2022-2032)
  • Table 17: Intranasal Drug Delivery Market in Italy (2022-2032)
  • Table 18: Intranasal Drug Delivery Market in Spain (2022-2032)
  • Table 19: Intranasal Drug Delivery Market in the Rest of Europe (2022-2032)
  • Table 20: Intranasal Drug Delivery Market in Asia-Pacific (2022-2032)
  • Table 21: Intranasal Drug Delivery Market in China (2022-2032)
  • Table 22: Intranasal Drug Delivery Market in Japan (2022-2032)
  • Table 23: Intranasal Drug Delivery Market in India (2022-2032)
  • Table 24: Intranasal Drug Delivery Market in Australia (2022-2032)
  • Table 25: Intranasal Drug Delivery Market in South Korea (2022-2032)
  • Table 26: Intranasal Drug Delivery Market in Rest of Asia-Pacific (2022-2032)
  • Table 27: Intranasal Drug Delivery Market in the Rest of the World (2022-2032)
  • Table 28: Intranasal Drug Delivery Market in the Middle East (2022-2032)
  • Table 29: Intranasal Drug Delivery Market in Africa (2022-2032)
  • Table 30: Intranasal Drug Delivery Market in South America (2022-2032)

List of Figures

  • Figure 1: Competitive Analysis
  • Figure 2: Intranasal Drug Delivery Market in Global (2022-2032)
  • Figure 3: Intranasal Drug Delivery Market in Global by Dosage Form (2022-2032)
  • Figure 4: Intranasal Drug Delivery Market in Global by Container (2022-2032)
  • Figure 5: Intranasal Drug Delivery Market in Global by System (2022-2032)
  • Figure 6: Intranasal Drug Delivery Market in Global by Application (2022-2032)
  • Figure 7: Intranasal Drug Delivery Market in Global by Distribution Channel (2022-2032)
  • Figure 8: Intranasal Drug Delivery Market in Global by Geography (2022-2032)
  • Figure 9: Intranasal Drug Delivery Market in North America (2022-2032)
  • Figure 10: Intranasal Drug Delivery Market in the United States (2022-2032)
  • Figure 11: Intranasal Drug Delivery Market in Canada (2022-2032)
  • Figure 12: Intranasal Drug Delivery Market in Mexico (2022-2032)
  • Figure 13: Intranasal Drug Delivery Market in Europe (2022-2032)
  • Figure 14: Intranasal Drug Delivery Market in France (2022-2032)
  • Figure 15: Intranasal Drug Delivery Market in Germany (2022-2032)
  • Figure 16: Intranasal Drug Delivery Market in United Kingdom (2022-2032)
  • Figure 17: Intranasal Drug Delivery Market in Italy (2022-2032)
  • Figure 18: Intranasal Drug Delivery Market in Spain (2022-2032)
  • Figure 19: Intranasal Drug Delivery Market in the Rest of Europe (2022-2032)
  • Figure 20: Intranasal Drug Delivery Market in Asia-Pacific (2022-2032)
  • Figure 21: Intranasal Drug Delivery Market in China (2022-2032)
  • Figure 22: Intranasal Drug Delivery Market in Japan (2022-2032)
  • Figure 23: Intranasal Drug Delivery Market in India (2022-2032)
  • Figure 24: Intranasal Drug Delivery Market in Australia (2022-2032)
  • Figure 25: Intranasal Drug Delivery Market in South Korea (2022-2032)
  • Figure 26: Intranasal Drug Delivery Market in Rest of Asia-Pacific (2022-2032)
  • Figure 27: Intranasal Drug Delivery Market in the Rest of the World (2022-2032)
  • Figure 28: Intranasal Drug Delivery Market in the Middle East (2022-2032)
  • Figure 29: Intranasal Drug Delivery Market in Africa (2022-2032)
  • Figure 30: Intranasal Drug Delivery Market in South America (2022-2032)
  • Figure 31: Market Drivers
  • Figure 32: Market Barriers
  • Figure 33: Marker Opportunities
  • Figure 34: PORTER'S Five Force Analysis
目次
Product Code: DIMDCL0492

Intranasal Drug Delivery Market by Dosage Form (Spray, Drops and Liquids, Gels, and Powders), Container (Pressurized and Non-pressurized), System (Unit-dose Systems, Bi-Dose Systems, and Multi-dose Systems), Application (Respiratory Disorders, Neurological Disorders, Infectious Diseases, and Others), Distribution Channel (Hospital & Retail Pharmacies and Online Pharmacies), and Geography (North America, Europe, Asia-Pacific, and Rest of the World) is expected to grow at a steady CAGR forecast till 2032 owing to The growing prevalence of chronic diseases and increasing R&D activities and product launches by key players in the domain of intranasal drug delivery.

The intranasal drug delivery market was valued at USD 64,451.20 million in 2024, growing at a CAGR of 6.24% during the forecast period from 2025 to 2032 to reach USD 104,248.63 million by 2032. This growth is primarily driven by the rising prevalence of chronic diseases, including neurological, respiratory, severe allergic, and ophthalmic disorders. The increasing demand for rapid-onset, non-invasive drug administration methods is also contributing to market expansion, as intranasal delivery offers fast absorption and ease of use, key factors in enhancing patient compliance and therapeutic outcomes. Moreover, heightened R&D activities and a surge in product launches by key industry players are further accelerating innovation in the field. These advancements are creating a dynamic and competitive landscape, fostering the development of more efficient and targeted intranasal therapies. Together, these trends are shaping a favorable environment for the sustained growth of the intranasal drug delivery market, positioning it for robust and consistent expansion throughout the forecast period from 2025 to 2032.

Intranasal Drug Delivery Market Dynamics:

According to the World Health Organization (2024), in 2023, epilepsy affected approximately 50 million people worldwide, making it one of the most common neurological disorders. Notably, around 80% of these cases occurred in low- and middle-income countries, where access to timely treatment remains limited. In such settings, intranasal drug delivery provides a practical, fast-acting alternative that can be administered without medical supervision. Such growing cases of epilepsy are driving the market growth as intranasal drug delivery is used for the acute treatment of intermittent episodes of increased seizure activity in patients with epilepsy.

Similarly, depression remains a major global health concern. As per WHO (2023), in 2023, an estimated 280 million people worldwide were living with depression. Intranasal therapies emerged as effective treatments for treatment-resistant depression, offering rapid symptom relief and easy administration, especially in outpatient and emergency care environments thereby creating the demand for intranasal drug delivery solutions.

The global diabetes burden is also rising rapidly. According to the International Diabetes Federation (2023), in 2021, there were 537 million adults (aged 20-79) living with diabetes, a number projected to increase to 643 million by 2030 and 783 million by 2045. Innovative intranasal formulations of hormones like glucagon provide a non-invasive, fast-acting alternative to injectable therapies, helping manage acute hypoglycemia in diabetic patients while bypassing hepatic metabolism. Therefore, rising cases of diabetes are driving the growth of the intranasal drug delivery market.

Additionally, chronic pain and migraine continue to affect large populations worldwide. According to the European Pain Federation (2023), in 2023, approximately 150 million people in Europe suffered from chronic pain. Meanwhile, the WHO (2024), estimated that migraine and other headache disorders affected 3.1 billion people globally in 2021. The demand for intranasal drug delivery solutions is increasing due to rising cases of migraine as these devices manage acute migraine attacks, offering quick relief by bypassing the gastrointestinal tract.

According to NHS England (2023), approximately 5.4 million individuals received treatment for asthma in 2023, with around 160,000 new diagnoses recorded annually in the United Kingdom. This rising prevalence of asthma is a significant driver of growth in the intranasal drug delivery market. Intranasal delivery presents a promising approach for asthma management, offering advantages such as ease of administration, rapid onset of action, and the ability to bypass first-pass metabolism. These benefits not only improve patient compliance but also enhance therapeutic efficiency, further contributing to the growing adoption of intranasal drug delivery systems in the treatment of respiratory conditions like asthma.

Conditions like depression, epilepsy, chronic pain, diabetes, and respiratory disorders often require medications that are either rapidly metabolized by the liver or difficult to administer orally during acute episodes. Intranasal drug delivery offers key advantages in such cases, including rapid absorption, avoidance of first-pass hepatic metabolism, and reduced side effects due to the lower doses required. Therefore, the growing prevalence of chronic diseases such as neurological disorders, respiratory conditions, and diabetes is significantly driving the growth of the intranasal drug delivery market.

The intranasal drug delivery market is further propelled by ongoing product approvals and launches from key industry players, reinforcing innovation and expanding treatment options. For example, in February 2025, Lupin Limited announced it had received approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Ipratropium Bromide Nasal Solution. This product is indicated for the symptomatic relief of rhinorrhea associated with both allergic and nonallergic perennial rhinitis in adults and children aged 6 years and older. Similarly, in April 2024, Amneal Pharmaceuticals received U.S. FDA approval for its Over-the-counter (OTC) Naloxone Hydrochloride Nasal Spray, intended for the emergency treatment of opioid overdose. These developments not only underscore the growing adoption of intranasal formulations but also highlight the increasing focus on accessibility, patient convenience, and rapid therapeutic response key factors fueling the market's sustained growth.

However, the complexities and limitations associated with the intranasal drug administration and stringent regulatory requirements for product approval, among others are some of the key constraints that may limit the growth of the intranasal drug delivery market.

Intranasal Drug Delivery Market Segment Analysis:

Intranasal Drug Delivery Market by Dosage Form (Spray, Drops and Liquids, Gels, and Powders), Container (Pressurized and Non-pressurized), System (Unit-dose Systems, Bi-Dose Systems, and Multi-dose Systems), Application (Respiratory Disorders, Neurological Disorders, Infectious Diseases, and Others), Distribution Channel (Hospital & Retail Pharmacies and Online Pharmacies), and Geography (North America, Europe, Asia-Pacific, and Rest of the World)

In the dosage form segment of the intranasal drug delivery market, the spray category is estimated to account for the largest market share in 2024. This robust growth is primarily driven by the increasing prevalence of respiratory diseases, severe allergic reactions, ophthalmic disorders, and neurological conditions, coupled with the multiple clinical and practical advantages offered by nasal sprays.

Nasal sprays are favored for their non-invasive, needle-free application, offering ease of administration and rapid onset of action are the factors that significantly enhance patient compliance and therapeutic efficiency. The nasal mucosa's highly vascularized and permeable surface enables efficient systemic absorption of drugs while bypassing the first-pass hepatic metabolism and avoiding gastrointestinal degradation. This leads to improved bioavailability, especially for drugs that are unstable or poorly absorbed through oral routes.

Moreover, nasal sprays are increasingly being utilized in the treatment of central nervous system (CNS) disorders. Their ability to deliver drugs via the olfactory and trigeminal nerve pathways allows for direct access to the brain, making them particularly effective in treating acute neurological conditions such as migraines, seizures, and opioid overdoses, where immediate therapeutic intervention is critical.

With the global burden of neurological diseases on the rise, leading pharmaceutical companies are intensifying their investments in research and development to introduce advanced intranasal spray formulations targeting these conditions. For example, in March 2023, Pfizer Inc. received FDA approval for ZAVZPRET(TM) (zavegepant), a CGRP receptor antagonist nasal spray indicated for the acute treatment of migraine, with or without aura, in adults. Similarly, in August 2023, Emergent BioSolutions launched NARCAN(R) Naloxone HCl Nasal Spray 4 mg, an over-the-counter (OTC) product designed for the emergency treatment of opioid overdose. These product innovations and regulatory milestones underscore the increasing clinical relevance of nasal sprays in both urgent care and chronic disease management. As such, the spray segment is poised for substantial expansion, driven by a convergence of therapeutic demand, technological advancement, and regulatory support.

Thus, the factors mentioned above are likely to boost the market segment and thereby increase the overall market of intranasal drug delivery across the globe.

North America is expected to dominate the overall intranasal drug delivery market:

North America is expected to hold the largest share of the intranasal drug delivery market in 2024, driven by several key factors. The region's dominance is primarily attributed to the rising prevalence of neurological, respiratory, and diabetes, which has created a growing demand for more effective and patient-friendly drug delivery solutions. Additionally, the increasing preference for rapid-onset therapies and the convenience of self-administration is significantly boosting the adoption of intranasal drug delivery systems across the region. Moreover, increase in regulatory approvals and new product launches by leading pharmaceutical companies with a strong pipeline of intranasal formulations, coupled with favorable healthcare infrastructure and awareness. Collectively, these factors are expected to sustain North America's leading position in the global market.

As per the data from the National Institute of Health (2023), in 2022, it was estimated that more than one in five adults were living with a mental illness (59.3 million) with 21 million people suffering from one major depressive disorder. Similarly, data from the Government of Canada (2023), in 2022, approximately 5 million people were suffering from mental disorders including major depressive disorders, anxiety, and seizures among others. Intranasal drug delivery devices with drugs are used for treatment-resistant depression and major depressive disorder with suicidal ideation.

According to the Centers for Disease Control and Prevention (2024), in 2022, approximately 2.9 million adults aged 18 and older in the U.S. reported having active epilepsy.

Additionally, data from the Anxiety & Depression Association of America (2022), revealed that 2 to 3% of individuals in the country experienced panic disorder, with women being twice as likely to be affected as men. Furthermore, generalized anxiety disorder (GAD) impacted around 6.8 million adults, or 3.1% of the U.S. population, underscoring the widespread burden of anxiety-related conditions.

The increasing incidence of such neurological and psychiatric disorders necessitates fast-acting, non-invasive treatment options, for which intranasal drug delivery offers a highly effective solution.

According to the Asthma and Allergy Foundation of America (2023), more than 27 million people in the United States were living with asthma in 2022, accounting for approximately 1 in every 12 individuals. Additionally, over 2 million adults aged 18 or older were affected by asthma. Data from the Allergy & Asthma Network (2023), further supported this, indicating that more than 26 million people, including 7% of adults and 6.5% of children, were living with asthma across the country.

Similarly, according to the Centers for Disease Control and Prevention (CDC, 2024), an estimated 16 million Americans have been diagnosed with chronic obstructive pulmonary disease (COPD). The data from the American Lung Association (2023), reported that 1.7 million individuals were diagnosed with COPD and other respiratory diseases, representing 4.6% of the U.S. population. The growing prevalence of asthma, COPD, and related respiratory conditions has led to a surging demand for intranasal drug delivery, which provides effective symptom relief and helps control disease progression.

The rising prevalence of asthma and chronic obstructive pulmonary disease (COPD) is driving growth in the intranasal drug delivery market in the region, as patients seek fast-acting, non-invasive therapies to manage respiratory symptoms like nasal congestion and airway inflammation. Intranasal corticosteroids and decongestants provide targeted relief with fewer systemic side effects, enhancing patient compliance and treatment effectiveness.

In addition to disease prevalence, regulatory advancements and product innovations are further fueling market growth. For instance, in September 2024, AstraZeneca announced that FluMist(R), the only self-administered influenza vaccine, was approved in the U.S. This needle-free nasal spray can be self-administered by adults up to 49 years old or administered by a caregiver to individuals aged 2-17, marking a major step forward in patient-friendly vaccine delivery.

Intranasal Drug Delivery Market Key Players:

Some of the key market players operating in the intranasal drug delivery market include Pfizer Inc., Johnson & Johnson Services, Inc., EMERGENT, UCB S.A., GSK plc, Amphastar Pharmaceuticals, Inc., Neurelis, Inc., Hikma Pharmaceuticals PLC, Perrigo Company, ARS Pharmaceuticals Operations, Inc., AstraZeneca, Therakind, AFT Pharmaceuticals, Teva Pharmaceutical Industries Ltd., Currax Pharmaceuticals LLC, Impel Pharmaceuticals LLC, Endo, Inc., Procter & Gamble, Teleflex Incorporated, Viatris, Inc., Amneal Pharmaceuticals LLC, and others.

Recent Developmental Activities in the Intranasal Drug Delivery Market:

  • In January 2025, Johnson & Johnson announced that the U.S. Food and Drug Administration (FDA) approved a supplemental New Drug Application (sNDA) for SPRAVATO(R) (esketamine) CIII nasal spray. This approval makes SPRAVATO(R) the first and only monotherapy specifically indicated for adults with major depressive disorder (MDD) who have had an inadequate response to at least two oral antidepressants.
  • In November 2024, Corxel Pharmaceuticals announced that the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) of the People's Republic of China (PRC) approved the New Drug Application (NDA) for varenicline solution nasal spray. This approval allowed the product to be marketed in China for the treatment of dry eye disease by increasing natural tear production, offering patients a novel, non-invasive therapeutic option.
  • In August 2024, ARS Pharmaceuticals received FDA approval for neffy(R) (epinephrine nasal spray), marking a groundbreaking advancement as the first and only needle-free epinephrine treatment for Type I allergic reactions, including life-threatening anaphylaxis. This approval represented a significant milestone in allergy care, offering patients and caregivers a rapid, effective, and more accessible alternative to traditional auto-injectors.
  • In January 2023, AstraZeneca announced the FDA approval of Airsupra (albuterol/budesonide), an as-needed inhaler for the treatment and prevention of bronchoconstriction and exacerbations in adults with asthma aged 18 years and older.

Key takeaways from the intranasal drug delivery market report study

  • Market size analysis for current intranasal drug delivery market size (2024), and market forecast for 8 years (2025 to 2032)
  • Top key product/technology developments, mergers, acquisitions, partnerships, and joint ventures happened over the last 3 years.
  • Key companies dominating the intranasal drug delivery market.
  • Various opportunities available for the other competitors in the intranasal drug delivery market space.
  • What are the top-performing segments in 2024? How these segments will perform in 2032?
  • Which are the top-performing regions and countries in the current intranasal drug delivery market scenario?
  • Which are the regions and countries where companies should have concentrated on opportunities for intranasal drug delivery market growth in the coming future?

Target audience who can benefit from this intranasal drug delivery market report study

  • Intranasal drug delivery product providers
  • Research organizations and consulting companies
  • Intranasal drug delivery-related organizations, associations, forums, and other alliances
  • Government and corporate offices
  • Start-up companies, venture capitalists, and private equity firms
  • Distributors and traders dealing in intranasal drug delivery
  • Various end-users who want to know more about the intranasal drug delivery market and the latest technological developments in the intranasal drug delivery market.

Frequently Asked Questions for the Intranasal Drug Delivery Market:

1. What is intranasal drug delivery?

  • Intranasal drug delivery is a method of administering medications through the nasal cavity for local or systemic effects. It offers rapid absorption due to the rich blood supply in the nasal mucosa and bypasses first-pass liver metabolism. This route is non-invasive, needle-free, and especially useful for emergency and CNS-related treatments.

2. What is the market for intranasal drug delivery?

  • The intranasal drug delivery market was valued at USD 64,451.20 million in 2024, growing at a CAGR of 6.24% during the forecast period from 2025 to 2032 to reach USD 104,248.63 million by 2032.

3. What are the drivers for the intranasal drug delivery market?

  • This growth is primarily driven by the rising prevalence of chronic diseases, including neurological, respiratory, severe allergic, and ophthalmic disorders. The increasing demand for rapid-onset, non-invasive drug administration methods is also contributing to market expansion, as intranasal delivery offers fast absorption and ease of use, key factors in enhancing patient compliance and therapeutic outcomes. Moreover, heightened R&D activities and a surge in product launches by key industry players are further accelerating innovation in the field. These advancements are creating a dynamic and competitive landscape, fostering the development of more efficient and targeted intranasal therapies. Together, these trends are shaping a favorable environment for the sustained growth of the intranasal drug delivery market, positioning it for robust and consistent expansion throughout the forecast period from 2025 to 2032.

4. Who are the key players operating in the intranasal drug delivery market?

  • Some of the key market players operating in the intranasal drug delivery market include Pfizer Inc., Johnson & Johnson Services, Inc., EMERGENT, UCB S.A., GSK plc, Amphastar Pharmaceuticals, Inc., Neurelis, Inc., Hikma Pharmaceuticals PLC, Perrigo Company, ARS Pharmaceuticals Operations, Inc., AstraZeneca, Therakind, AFT Pharmaceuticals, Teva Pharmaceutical Industries Ltd., Currax Pharmaceuticals LLC, Impel Pharmaceuticals LLC, Endo, Inc., Procter & Gamble, Teleflex Incorporated, Viatris, Inc., Amneal Pharmaceuticals LLC, and others.

5. Which region has the highest share in the intranasal drug delivery market?

  • North America is expected to hold the largest share of the intranasal drug delivery market in 2024, driven by several key factors. The region's dominance is primarily attributed to the rising prevalence of neurological, respiratory, and diabetes, which has created a growing demand for more effective and patient-friendly drug delivery solutions. Additionally, the increasing preference for rapid-onset therapies and the convenience of self-administration is significantly boosting the adoption of intranasal drug delivery systems across the region. Moreover, increase in regulatory approvals and new product launches by leading pharmaceutical companies with a strong pipeline of intranasal formulations, coupled with favorable healthcare infrastructure and awareness. Collectively, these factors are expected to sustain North America's leading position in the global market.

Table of Contents

1. Intranasal Drug Delivery Market Report Introduction

  • 1.1 Scope of the Study
  • 1.2 Market Segmentation
  • 1.3 Market Assumption

2. Intranasal Drug Delivery Market Executive Summary

  • 2.1 Market at Glance

3. Competitive Landscape

4. Regulatory Analysis

  • 4.1 The United States
  • 4.2 Europe
  • 4.3 Japan
  • 4.4 China

5. Intranasal Drug Delivery Market Key Factors Analysis

  • 5.1 Intranasal Drug Delivery Market Drivers
    • 5.1.1 The growing prevalence of chronic diseases
    • 5.1.2 Rising demand for rapid onset and non-invasive drug administration
    • 5.1.3 Increasing R&D activities and product launches by key players in the domain of intranasal drug delivery diseases
  • 5.2 Intranasal Drug Delivery Market Restraints and Challenges
    • 5.2.1 Complexities and limitations associated with the intranasal drug administration
    • 5.2.2 Stringent regulatory requirements for product approval
  • 5.3 Intranasal Drug Delivery Market Opportunity
    • 5.3.1 Advancements in nano-formulations and personalized medicine

6. Intranasal Drug Delivery Market Porter's Five Forces Analysis

  • 6.1 Bargaining Power of Suppliers
  • 6.2 Bargaining Power of Consumers
  • 6.3 Threat of New Entrants
  • 6.4 Threat of Substitutes
  • 6.5 Competitive Rivalry

7. Intranasal Drug Delivery Market Assessment

  • 7.1 By Dosage Form
    • 7.1.1 Spray
    • 7.1.2 Drops and Liquids
    • 7.1.3 Gels
    • 7.1.4 Powders
  • 7.2 By Container
    • 7.2.1 Pressurized
    • 7.2.2 Non-pressurized
  • 7.3 By System
    • 7.3.1 Unit-dose Systems
    • 7.3.2 Bi-Dose Systems
    • 7.3.3 Multi-dose Systems
  • 7.4 By Application
    • 7.4.1 Respiratory Disorders
    • 7.4.2 Neurological Disorders
    • 7.4.3 Infectious Diseases
    • 7.4.4 Others
  • 7.5 By Distribution Channel
    • 7.5.1 Hospital & Retail Pharmacies
    • 7.5.2 Online Pharmacies
  • 7.6 By Geography
    • 7.6.1 North America
      • 7.6.1.1 United States Intranasal Drug Delivery Market Size in USD million (2022-2032)
      • 7.6.1.2 Canada Intranasal Drug Delivery Market Size in USD million (2022-2032)
      • 7.6.1.3 Mexico Intranasal Drug Delivery Market Size in USD million (2022-2032)
    • 7.6.2 Europe
      • 7.6.2.1 France Intranasal Drug Delivery Market Size in USD million (2022-2032)
      • 7.6.2.2 Germany Intranasal Drug Delivery Market Size in USD million (2022-2032)
      • 7.6.2.3 United Kingdom Intranasal Drug Delivery Market Size in USD million (2022-2032)
      • 7.6.2.4 Italy Intranasal Drug Delivery Market Size in USD million (2022-2032)
      • 7.6.2.5 Spain Intranasal Drug Delivery Market Size in USD million (2022-2032)
      • 7.6.2.6 Rest of Europe Intranasal Drug Delivery Market Size in USD million (2022-2032)
    • 7.6.3 Asia-Pacific
      • 7.6.3.1 China Intranasal Drug Delivery Market Size in USD million (2022-2032)
      • 7.6.3.2 Japan Intranasal Drug Delivery Market Size in USD million (2022-2032)
      • 7.6.3.3 India Intranasal Drug Delivery Market Size in USD million (2022-2032)
      • 7.6.3.4 Australia Intranasal Drug Delivery Market Size in USD million (2022-2032)
      • 7.6.3.5 South Korea Intranasal Drug Delivery Market Size in USD million (2022-2032)
      • 7.6.3.6 Rest of Asia-Pacific Intranasal Drug Delivery Market Size in USD million (2022-2032)
    • 7.6.4 Rest of the World (RoW)
      • 7.6.4.1 Middle East Intranasal Drug Delivery Market Size in USD million (2022-2032)
      • 7.6.4.2 Africa Intranasal Drug Delivery Market Size in USD million (2022-2032)
      • 7.6.4.3 South America Intranasal Drug Delivery Market Size In USD Million (2022-2032)

8. Intranasal Drug Delivery Market Company and Product Profiles

  • 8.1 Pfizer Inc.
    • 8.1.1 Company Overview
    • 8.1.2 Company Snapshot
    • 8.1.3 Financial Overview
    • 8.1.4 Product Listing
    • 8.1.5 Entropy
  • 8.2 Johnson & Johnson Services, Inc.
    • 8.2.1 Company Overview
    • 8.2.2 Company Snapshot
    • 8.2.3 Financial Overview
    • 8.2.4 Product Listing
    • 8.2.5 Entropy
  • 8.3 EMERGENT
    • 8.3.1 Company Overview
    • 8.3.2 Company Snapshot
    • 8.3.3 Financial Overview
    • 8.3.4 Product Listing
    • 8.3.5 Entropy
  • 8.4 UCB S.A.
    • 8.4.1 Company Overview
    • 8.4.2 Company Snapshot
    • 8.4.3 Financial Overview
    • 8.4.4 Product Listing
    • 8.4.5 Entropy
  • 8.5 GSK plc
    • 8.5.1 Company Overview
    • 8.5.2 Company Snapshot
    • 8.5.3 Financial Overview
    • 8.5.4 Product Listing
    • 8.5.5 Entropy
  • 8.6 Amphastar Pharmaceuticals, Inc.
    • 8.6.1 Company Overview
    • 8.6.2 Company Snapshot
    • 8.6.3 Financial Overview
    • 8.6.4 Product Listing
    • 8.6.5 Entropy
  • 8.7 Neurelis, Inc.
    • 8.7.1 Company Overview
    • 8.7.2 Company Snapshot
    • 8.7.3 Financial Overview
    • 8.7.4 Product Listing
    • 8.7.5 Entropy
  • 8.8 Hikma Pharmaceuticals PLC
    • 8.8.1 Company Overview
    • 8.8.2 Company Snapshot
    • 8.8.3 Financial Overview
    • 8.8.4 Product Listing
    • 8.8.5 Entropy
  • 8.9 Perrigo Company
    • 8.9.1 Company Overview
    • 8.9.2 Company Snapshot
    • 8.9.3 Financial Overview
    • 8.9.4 Product Listing
    • 8.9.5 Entropy
  • 8.10. ARS Pharmaceuticals Operations, Inc.
    • 8.10.1 Company Overview
    • 8.10.2 Company Snapshot
    • 8.10.3 Financial Overview
    • 8.10.4 Product Listing
    • 8.10.5 Entropy
  • 8.11 AstraZeneca
    • 8.11.1 Company Overview
    • 8.11.2 Company Snapshot
    • 8.11.3 Financial Overview
    • 8.11.4 Product Listing
    • 8.11.5 Entropy
  • 8.12. Therakind
    • 8.12.1 Company Overview
    • 8.12.2 Company Snapshot
    • 8.12.3 Financial Overview
    • 8.12.4 Product Listing
    • 8.12.5 Entropy
  • 8.13. AFT Pharmaceuticals
    • 8.13.1 Company Overview
    • 8.13.2 Company Snapshot
    • 8.13.3 Financial Overview
    • 8.13.4 Product Listing
    • 8.13.5 Entropy
  • 8.14. Teva Pharmaceutical Industries Ltd.
    • 8.14.1 Company Overview
    • 8.14.2 Company Snapshot
    • 8.14.3 Financial Overview
    • 8.14.4 Product Listing
    • 8.14.5 Entropy
  • 8.15 Currax Pharmaceuticals LLC
    • 8.15.1 Company Overview
    • 8.15.2 Company Snapshot
    • 8.15.3 Financial Overview
    • 8.15.4 Product Listing
    • 8.15.5 Entropy
  • 8.16 Impel Pharmaceuticals LLC
    • 8.16.1 Company Overview
    • 8.16.2 Company Snapshot
    • 8.16.3 Financial Overview
    • 8.16.4 Product Listing
    • 8.16.5 Entropy
  • 8.17. Endo, Inc.
    • 8.17.1 Company Overview
    • 8.17.2 Company Snapshot
    • 8.17.3 Financial Overview
    • 8.17.4 Product Listing
    • 8.17.5 Entropy
  • 8.18. Procter & Gamble
    • 8.18.1 Company Overview
    • 8.18.2 Company Snapshot
    • 8.18.3 Financial Overview
    • 8.18.4 Product Listing
    • 8.18.5 Entropy
  • 8.19. Teleflex Incorporated
    • 8.19.1 Company Overview
    • 8.19.2 Company Snapshot
    • 8.19.3 Financial Overview
    • 8.19.4 Product Listing
    • 8.19.5 Entropy
  • 8.20. Viatris Inc.
    • 8.20.1 Company Overview
    • 8.20.2 Company Snapshot
    • 8.20.3 Financial Overview
    • 8.20.4 Product Listing
    • 8.20.5 Entropy
  • 8.21. Amneal Pharmaceuticals LLC
    • 8.21.1 Company Overview
    • 8.21.2 Company Snapshot
    • 8.21.3 Financial Overview
    • 8.21.4 Product Listing
    • 8.21.5 Entropy

9. KOL Views

10. Project Approach

11. About DelveInsight

12. Disclaimer & Contact Us